RECORNABIO

Technology

Platform Technology

RecoRNA(Guangzhou) Biotechnology Co., Ltd

Xu Xin (Hong Kong) Biotechnology Co., Ltd

RecoRNA(Guangzhou) Biotechnology Co., Ltd, is a pioneering biotechnology company focused on the development of RNA-targeted editing technologies to tackle diseases that currently lack effective conventional treatments. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies.

RecoRNA possesses RNA therapy platform, which includes a world-leading RNA single-base editing design platform based on the world’s largest ADAR substrate editing library, a RNA fragment excising tool,and the AI-driven ATOMIC screening platform.These breakthrough innovations provide strong support and assurance for the company's research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.

Xu Xin (Hong Kong) Biotechnology Co., Ltd.,a wholly-owned subsidiary of RecoRNA(Guangzhou) Biotechnology Co., Ltd, at the Hong Kong Science Park. It has built an AI technology platform that overcomes the bottleneck of traditional R&D, and accelerate the entire process from target discovery, lead optimization and candidate selection.

Target Identification:

MIRROR*（RNA single base editing tool）

Aided by the world‘s largest ADAR*^ substrate editing library1,2 with independent IP rights, gRNA (guided RNA) can be designed to achieve accurate and efficient RNA editing by endogenous adenosine deaminase (ADAR). The editing efficiency is up to 95% in vitro and up to 80% in vivo.

SCISSOR*（RNA fragment excising tool）

The world's first-ever RNA fragment excising tool, covered with independent IP rights, enables the removal of 3-24 number of bases at the RNA level. This breakthrough technology opens up new avenues for the repair of frameshift mutations and the generation of frameshift neoantigens, filling the gap in this global field.

*：Nature Biotechnology，2025; DOI: 10.1038/s41587-025-02628-6.

^：Nature Structural & Molecular Biology, 2020; DOI:10.1038/s41594-020-0398-4

**：Molecular Cell，2025；DOI: 10.1016/j.molcel.2025.01.021.

ATOMIC Platform（AI-driven R&D Platform）

powered by the ATOMIC platform, the whole process from target discovery to lead generation is significantly accelerated.

Molecule Design and Optimization:

with AI assistance, the efficiency and success rate of drug molecule design are greatly improved.

Preclinical and Clinical Development:

through AI analysis, the efficacy and PKDM properties of early drug candidates can be evaluated and predicted, thus to achieve optimized clinical trial design, which can reduce the failure rate of clinical studies and accelerate the drug approval process.

粤ICP备2022119292号-1